Current cytogenetic and molecular responses of patients of groups 1 (eligible for HSCT, donor available; n = 113) and 2 (no related donor available, no MUD transplantation in any phase; n = 92) surviving at least 5 years
| . | Group 1: eligible for HSCT, related donor available . | Group 2: eligible for HSCT, no related donor available, no MUD transplantation . |
|---|---|---|
| No. patients | 113 | 92 |
| Median follow-up (range), y | 6.6 (4.1-10.8) | 8.1 (4.6-10.0) |
| Evaluable for cytogenetic response, no. (%) | 55 (49) | 52 (57) |
| Median proportion of Ph+ metaphases, % | 0 | 8 |
| Complete cytogenetic response, Ph+ of 0%, no. (%) | 50 (91) | 25 (48) |
| Major cytogenetic response, Ph+ less than 35%, no. (%) | 50 (91) | 32 (61) |
| Evaluable for molecular response, no. (%) | 58 (51) | 40 (43) |
| Median ratio BCR-ABL/ABL, % | 0 | 0.19 |
| Undetectable BCR-ABL, no. (%) | 42 (72) | 4 (10) |
| Major molecular response, BCR-ABL/ABL ratio less than 0.1%, no. (%) | 47 (81) | 18 (45) |
| . | Group 1: eligible for HSCT, related donor available . | Group 2: eligible for HSCT, no related donor available, no MUD transplantation . |
|---|---|---|
| No. patients | 113 | 92 |
| Median follow-up (range), y | 6.6 (4.1-10.8) | 8.1 (4.6-10.0) |
| Evaluable for cytogenetic response, no. (%) | 55 (49) | 52 (57) |
| Median proportion of Ph+ metaphases, % | 0 | 8 |
| Complete cytogenetic response, Ph+ of 0%, no. (%) | 50 (91) | 25 (48) |
| Major cytogenetic response, Ph+ less than 35%, no. (%) | 50 (91) | 32 (61) |
| Evaluable for molecular response, no. (%) | 58 (51) | 40 (43) |
| Median ratio BCR-ABL/ABL, % | 0 | 0.19 |
| Undetectable BCR-ABL, no. (%) | 42 (72) | 4 (10) |
| Major molecular response, BCR-ABL/ABL ratio less than 0.1%, no. (%) | 47 (81) | 18 (45) |